Draxis Extends Maintenance Shutdown of Contract Manufacturing Facility

Article

Draxis Extends Maintenance Shutdown of Contract Manufacturing Facility

Draxis Pharma, the pharmaceutical contract manufacturing division of Draxis Health Inc. (Mississauga, ON, Canada), has extended its scheduled summer maintenance shutdown of its sterile and lyophilized product manufacturing areas. The shutdown was extended to allow the company to replace a major electrical panel and a pump assembly, and to perform "further cleaning and decontamination of the sterile production area," according to a company statement. The shutdown, originally scheduled to last two to three weeks, is now expected to last five to seven weeks. Company officials declined to provide additional details until they issue a follow-up announcement about the resumption of production.


–Laura Bush

Recent Videos
Drug Digest: Challenges and Triumphs in Next-Generation Biotherapeutic Development
Industry Outlook 2025: The Rising Prominence of AI in Pharma
Leroy Hood, MD, PhD
Related Content